Hope for muscle stiffness: new drug shows promise in Long-Term trial
NCT ID NCT06549400
First seen Jan 26, 2026 · Last updated May 15, 2026 · Updated 14 times
Summary
This study looks at the long-term safety and effectiveness of a daily medication called mexiletine PR for reducing muscle stiffness (myotonia) in people with myotonic dystrophy types 1 and 2. It is for those who have already completed a previous study of the same drug. The goal is to see if the drug continues to work well and remains safe over 26 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOTONIC DYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aarhus University Hospital
Aarhus, Denmark
-
Azienda Ospedaliera Universitaria Policlinico Tor Vergata
Rome, Italy
-
Laboratory for Muscle Diseases and Neuropathies
Leuven, Belgium
-
Ludug-Maximilians University
München, Germany
-
University College Hospital
London, United Kingdom
-
University Hospital of Madrid
Madrid, Spain
Conditions
Explore the condition pages connected to this study.